Volume 75, Issue 3, Pages (March 2019)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 155, Issue 3, Pages (March 1996)

Volume 60, Issue 2, Pages (August 2011)

European Urology Focus

Volume 58, Issue 4, Pages (October 2010)

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer Miguel.

Volume 70, Issue 6, Pages (December 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 60, Issue 2, Pages (August 2011)

Volume 67, Issue 4, Pages (April 2015)

Volume 74, Issue 2, Pages (August 2018)

European Urology Oncology

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 70, Issue 4, Pages (October 2016)

Volume 68, Issue 2, Pages (August 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 52, Issue 3, Pages (September 2007)

Volume 49, Issue 5, Pages (May 2006)

Volume 74, Issue 4, Pages (October 2018)

Volume 65, Issue 5, Pages (May 2014)

Volume 74, Issue 1, Pages (July 2018)

A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.

Volume 65, Issue 3, Pages (March 2014)

Volume 65, Issue 1, Pages (January 2014)

Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward Takuma Uo, Cynthia Sprenger European Urology

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 70, Issue 4, Pages (October 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 70, Issue 5, Pages (November 2016)

Volume 66, Issue 3, Pages (September 2014)

Volume 70, Issue 5, Pages (November 2016)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 70, Issue 4, Pages (October 2016)

Laurent Boccon-Gibod European Urology Supplements

Yuanshan Cui, Yong Zhang European Urology

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

Volume 73, Issue 5, Pages (May 2018)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Volume 74, Issue 2, Pages (August 2018)

Volume 67, Issue 1, Pages (January 2015)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

Volume 73, Issue 5, Pages (May 2018)

Volume 71, Issue 6, Pages (June 2017)

Volume 55, Issue 6, Pages (June 2009)

Volume 49, Issue 4, Pages (April 2006)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 70, Issue 6, Pages (December 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 74, Issue 3, Pages (September 2018)

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Highlighting Unmet Needs: Real Patients, Difficult Choices

Volume 53, Issue 6, Pages (June 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 76, Issue 1, Pages (July 2019)

European Urology Oncology

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Volume 75, Issue 3, Pages 368-373 (March 2019) Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C. Villa-Guzmán, Susana Hernando, Alejo Rodriguez-Vida, Aránzazu González-del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi European Urology Volume 75, Issue 3, Pages 368-373 (March 2019) DOI: 10.1016/j.eururo.2018.09.049 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Study design and association of plasma AR status with clinical outcome in castration-resistant prostate cancer patients treated with docetaxel. (A) Flow chart showing the selection of docetaxel-treated patients for the primary and exploratory analyses. (B) Overall survival and (C) progression-free survival in docetaxel-treated patients. (D) Waterfall plots depicting prostate-specific antigen (PSA) declines (%) by AR copy number normal and gain in docetaxel-treated patients. Bars clipped at maximum 100%. AR=androgen receptor; CN=copy number; CRPC=castration-resistant prostate cancer; doce=docetaxel; OS=overall survival; PFS=progression-free survival. European Urology 2019 75, 368-373DOI: (10.1016/j.eururo.2018.09.049) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Association of plasma AR status with clinical outcome in castration-resistant prostate cancer patients treated with either docetaxel or AR-directed therapies (abiraterone or enzalutamide) as first-line treatment. Interaction between AR status and treatment type, after including data from abiraterone- or enzalutamide-treated patients for (A) OS and (B) PFS. (C) Forest plot shows the hazard ratio and 95% confidence interval for (C) OS and (D) PFS in AR-normal and AR-gained patients. Abi=abiraterone, AR= androgen receptor; doce=docetaxel; enza=enzalutamide; OS=overall survival; PFS=progression-free survival. European Urology 2019 75, 368-373DOI: (10.1016/j.eururo.2018.09.049) Copyright © 2018 The Authors Terms and Conditions